AR108824A1 - Derivados de anticuerpos contra el vih con actividad dual antiviral e inmunomodulatoria - Google Patents

Derivados de anticuerpos contra el vih con actividad dual antiviral e inmunomodulatoria

Info

Publication number
AR108824A1
AR108824A1 ARP160103527A ARP160103527A AR108824A1 AR 108824 A1 AR108824 A1 AR 108824A1 AR P160103527 A ARP160103527 A AR P160103527A AR P160103527 A ARP160103527 A AR P160103527A AR 108824 A1 AR108824 A1 AR 108824A1
Authority
AR
Argentina
Prior art keywords
antibody derivatives
human
hiv
pharmaceutical composition
sample
Prior art date
Application number
ARP160103527A
Other languages
English (en)
Inventor
Arbus Julin M Blanco
Sala Bonaventura Clotet
Molina Jorge Carrillo
Original Assignee
Fundacio Privada Inst De Recerca De La Sida Caixa Irsicaixa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Privada Inst De Recerca De La Sida Caixa Irsicaixa filed Critical Fundacio Privada Inst De Recerca De La Sida Caixa Irsicaixa
Publication of AR108824A1 publication Critical patent/AR108824A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2

Abstract

Los derivados de anticuerpos de la presente solicitud se caracterizan por tener una mayor capacidad para (i) bloquear la entrada del virus de la inmunodeficiencia humana (VIH) a células huésped e (ii) inducir la activación de células asesinas naturales (NK) y otras células del sistema inmune. Varias formas de estos polipéptidos se describen y ejemplifican aquí. La presente también incluye las secuencias aisladas de ácidos nucleicos, vectores y células huésped que expresan dichos polipéptidos, al igual que sus aplicaciones terapéuticas y diagnósticas en salud humana. Reivindicación 1: Derivados de anticuerpos que comprenden del extremo N-terminal en dirección al extremo C-terminal: a) los dominios extracelulares D1 y D2 del receptor CD4 humano, b) el segmento Fc de una inmunoglobulina G humana, c) una fracción seleccionada del grupo que consiste de: i) un conector peptídico de secuencia (GGGGS)ₙ donde 1 £ n £ 10, ii) la secuencia del receptor CCR5 humano y iii) combinaciones de (i) y (ii), y d) un polipéptido derivado de gp41. Reivindicación 10: Una composición farmacéutica que comprende una cantidad terapéuticamente efectiva de los derivados de anticuerpos según cualesquiera de las reivindicaciones 1 a 5, las secuencias de nucleótidos de acuerdo a las reivindicaciones 6 ó 7, el vector de expresión de acuerdo a la reivindicación 8, la célula huésped de acuerdo a la reivindicación 9 o una mezcla de ellos. Reivindicación 13: Derivados de anticuerpos según cualesquiera de las reivindicaciones 1 a 5, las secuencias de nucleótidos de acuerdo a las reivindicaciones 6 ó 7, el vector de expresión de acuerdo a la reivindicación 8, la célula huésped de acuerdo a la reivindicación 9 o la composición farmacéutica de acuerdo a la reivindicación 10, para su uso en la prevención del VIH o el SIDA. Reivindicación 18: Un método para inducir la expresión de gp120 en una célula infectada de VIH que comprende contactar la célula infectada con los derivados de anticuerpos según cualesquiera de las reivindicaciones 1 a 5, las secuencias de nucleótidos de acuerdo a las reivindicaciones 6 ó 7, el vector de expresión de acuerdo a la reivindicación 8, la célula huésped de acuerdo a la reivindicación 9, la composición farmacéutica de acuerdo a la reivindicación 10, la combinación de acuerdo a las reivindicaciones 14 ó 15 o una mezcla de ellos. Reivindicación 19: Un método para detectar VIH en una muestra que comprende (a) contactar la muestra con los derivados de anticuerpos según cualesquiera de las reivindicaciones 1 a 5 y (b) determinar si los derivados de anticuerpos se acoplan específicamente a una molécula de la muestra.
ARP160103527A 2015-11-21 2016-11-18 Derivados de anticuerpos contra el vih con actividad dual antiviral e inmunomodulatoria AR108824A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201514948274A 2015-11-21 2015-11-21

Publications (1)

Publication Number Publication Date
AR108824A1 true AR108824A1 (es) 2018-10-03

Family

ID=58094460

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103527A AR108824A1 (es) 2015-11-21 2016-11-18 Derivados de anticuerpos contra el vih con actividad dual antiviral e inmunomodulatoria

Country Status (8)

Country Link
US (1) US11866479B2 (es)
EP (2) EP3377524B1 (es)
JP (2) JP6991138B2 (es)
CN (1) CN108699131A (es)
AR (1) AR108824A1 (es)
ES (1) ES2910415T3 (es)
UY (1) UY36990A (es)
WO (1) WO2017085563A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020519309A (ja) * 2017-05-10 2020-07-02 アルバジュナ・セラピューティクス・エセ・エレ 高い二重のＨＩＶ抗ウイルス及び免疫調節活性を有するＦｃ融合タンパク質誘導体
CN110846344A (zh) * 2019-11-18 2020-02-28 山东省齐鲁细胞治疗工程技术有限公司 一种表达il-6r阻断抗体的靶向cd19的嵌合抗原受体t细胞及制备方法、应用
WO2023205670A2 (en) * 2022-04-19 2023-10-26 Purdue Research Foundation Stable fc fragments, conjugates, compositions, and methods of use
CN116554356B (zh) * 2023-05-16 2024-01-23 武汉大学 一种hyperIL-15与sCD4及Fc的融合蛋白及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US5877159A (en) 1995-05-03 1999-03-02 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same
US5824538A (en) 1995-09-06 1998-10-20 The United States Of America As Represented By The Secretary Of The Army Shigella vector for delivering DNA to a mammalian cell
AU750106B2 (en) 1997-10-07 2002-07-11 University Of Maryland Biotechnology Institute Method for introducing and expressing RNA in animal cells
US7138119B2 (en) 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
AU2002363465A1 (en) * 2001-10-25 2003-05-19 The Government Of The United States Of America As Represented By The Secretary Of Health And Human S Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4
US20100249022A1 (en) * 2007-05-18 2010-09-30 University Of Massachusetts Strategy for cloning and expressing the extracellular domains of receptors as soluble proteins
GB0720503D0 (en) * 2007-10-22 2007-11-28 Angeletti P Ist Richerche Bio New compound
EP2566493B1 (en) * 2010-05-03 2015-03-04 New York Blood Center, Inc. Bifunctional molecules for inactivating hiv and blocking hiv
US20110305670A1 (en) * 2010-06-10 2011-12-15 President And Fellows Of Harvard College Nucleic acid encoding fusion polypeptides that prevent or inhibit hiv infection

Also Published As

Publication number Publication date
JP2019521639A (ja) 2019-08-08
US20210238252A1 (en) 2021-08-05
JP6991138B2 (ja) 2022-02-03
WO2017085563A1 (en) 2017-05-26
US11866479B2 (en) 2024-01-09
EP3377524A1 (en) 2018-09-26
ES2910415T3 (es) 2022-05-12
CN108699131A (zh) 2018-10-23
EP3377524B1 (en) 2022-01-26
EP4059956A1 (en) 2022-09-21
UY36990A (es) 2017-11-30
JP2022008978A (ja) 2022-01-14

Similar Documents

Publication Publication Date Title
PE20191648A1 (es) Nuevos receptores de celulas t y terapia inmunologica que los utiliza
AR108824A1 (es) Derivados de anticuerpos contra el vih con actividad dual antiviral e inmunomodulatoria
AR095432A1 (es) Proteínas de unión a antígeno
PE20191463A1 (es) Anticuerpos biespecificos de union especifica pd1 y lag3
PE20190418A1 (es) Anticuerpos contra proteina 3 que contiene el dominio de mucina e inmunoglobulina de linfocitos t (tim3) y sus usos
PE20190911A1 (es) Composiciones y anticuerpos anti-lag-3
Mangino et al. HIV-1 Nef induces proinflammatory state in macrophages through its acidic cluster domain: involvement of TNF alpha receptor associated factor 2
CL2013003634A1 (es) Complejo que comprende una proteina de fusion que comprende, un peptido viral, peptido conector, microglobulina beta 2 , peptido conector, dominios extracelulares alfa 1, 2 y 3 de mhc de clase i y un tercer peptido conector; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso
JP2019501882A5 (es)
PE20190477A1 (es) Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos
BR112016027805A2 (pt) receptores de células t do anti-papilomavírus humano 16 e7
Silvin et al. Innate immune sensing of HIV infection
AR079114A1 (es) Proteinas de enlace de antigenos anti-orai1 y usos de las mismas
PE20210376A1 (es) Peptidos y combinacion de peptidos de origen no canonico para el uso en la inmunoterapia contra diferentes tipos de cancer
CL2013003248A1 (es) Composición inmunogenica que comprende una glucoproteina g de los virus hendra y nipah y un complejo inmunoestimulante; método para producir una respuesta de anticuerpo neutralizante contra un virus hendra y/o nipah en un sujeto.
PE20171336A1 (es) Anticuerpos contra tau y sus usos
AR075047A1 (es) Metodos y composiciones en base a la proteina tipo 2 de la toxina shiga. polipeptido purificado. anticuerpo ant-stx2. kit.
JP2015212284A5 (es)
Gao et al. Designing a soluble near full-length HIV-1 gp41 trimer
Contarino et al. Chimeric Cyanovirin-MPER recombinantly engineered proteins cause cell-free virolysis of HIV-1
PE20191617A1 (es) Peptidos y combinaciones de peptidos para el uso en la inmunoterapia contra la leucemia y otros tipos de cancer
PE20210918A1 (es) Composiciones y metodos para el tratamiento de la distrofia macular
ES2828086T3 (es) Confórmeros abiertos de HLA-B57
RU2015130287A (ru) Адаптация вируса гриппа н5 к человеку
BR112019007343A2 (pt) sequência de nucleotídeos expressando uma proteína de ancoragem de exossomo para uso como vacina